Results

Total Results: over 10,000 records

Showing results for "depression".
Users also searched for: guidelines

1. Adolescent Depression Monitoring (pdf file)
   www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-248-fullreport.pdf
   December 01, 2019 - Depressive symptoms can be both prolonged and episodic, recurring over weeks and months (National Research … tracking of treatment goals and outcomes, including assessment of depressive symptoms and functioning … Additionally, minority adolescents may present depressive symptoms differently from non-Latino whites … The use of standardized tools is essential for tracking depressive symptoms and monitoring patient response … Measuring and tracking depressive symptoms is important to improve patient outcomes (Knaup, et al.,

2. Depression
   hcup-us.ahrq.gov/reports/factsandfigures/figures/2006/2006_5_2a.jsp
   January 01, 2006 - Depression Distribution of Discharges with a Principal Diagnosis of Depression† and All Discharges … by Age Group,* 2006 AGE GROUP PERCENT DISTRIBUTION DEPRESSION ALL DISCHARGES Ages

3. Depression
   hcup-us.ahrq.gov/reports/factsandfigures/figures/2006/2006_5_2b.jsp
   January 01, 2006 - Depression Percent of Depression Stays with Secondary Chronic Conditions or Secondary Mental … Health and Substance Abuse Diagnoses by Age, 2006 SEONDARY CONDITION TYPE PERCENT OF DEPRESSION

4. Depression
   hcup-us.ahrq.gov/reports/factsandfigures/figures/2006/2006_5_2c.jsp
   January 01, 2006 - Depression Discharge Prevalence for Depression by Median Income of Patient Zip Code, 2006

5. Depression
   hcup-us.ahrq.gov/reports/factsandfigures/figures/2006/2006_5_2d.jsp
   January 01, 2006 - Depression Discharge Prevalence for Depression by Region, 2006 REGION DISCHARGES PER

6. #05 DEPRESSION (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1406.pdf
   June 01, 2014 - symptoms compared with patients receiving traditional in- person therapy sessions. … symptoms and suicidal ideations within 40 minutes compared with placebo. … symptoms were randomly assigned to complete SPARX or standard in-person behavioral therapy. … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

7. #05 DEPRESSION (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1406.pdf
   June 01, 2014 - symptoms compared with patients receiving traditional in- person therapy sessions. … symptoms and suicidal ideations within 40 minutes compared with placebo. … symptoms were randomly assigned to complete SPARX or standard in-person behavioral therapy. … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

8. #05 DEPRESSION (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1412.pdf
   December 01, 2014 - symptoms compared with symptoms of patients receiving traditional in-person therapy sessions. … symptoms and suicidal ideations within 40 minutes compared with placebo. … , potentially restoring normal emotional processing and easing depressive symptoms.69 Clinical data … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

9. #05 DEPRESSION (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1412.pdf
   December 01, 2014 - symptoms compared with symptoms of patients receiving traditional in-person therapy sessions. … symptoms and suicidal ideations within 40 minutes compared with placebo. … , potentially restoring normal emotional processing and easing depressive symptoms.69 Clinical data … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

10. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - For many patients, single ketamine doses often reduce depressive symptoms within 2 hours, with improvements … symptoms within a few hours or days, exponentially faster than many approved antidepressants.12,13 … symptoms and suicidal ideation within 40 minutes compared with placebo. … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major

11. #05 DEPRESSION (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - For many patients, single ketamine doses often reduce depressive symptoms within 2 hours, with improvements … symptoms within a few hours or days, exponentially faster than many approved antidepressants.12,13 … symptoms and suicidal ideation within 40 minutes compared with placebo. … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major

12. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1306.pdf
    October 01, 2014 - believe that dysfunction in glutamate neurotransmission may play a major role in the etiology of depressive … symptoms in both bipolar disorder and MDD, although its exact mechanism of action is still unknown … symptoms improved both significantly and rapidly and that these effects lasted from 3 days to several … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

13. #05 DEPRESSION (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1306.pdf
    October 01, 2014 - believe that dysfunction in glutamate neurotransmission may play a major role in the etiology of depressive … symptoms in both bipolar disorder and MDD, although its exact mechanism of action is still unknown … symptoms improved both significantly and rapidly and that these effects lasted from 3 days to several … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

14. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/05_depression_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - believe that dysfunction in glutamate neurotransmission may play a major role in the etiology of depressive … symptoms in both bipolar disorder and MDD, although its exact mechanism of action is still unknown … symptoms improved both significantly and rapidly and that these effects lasted from 3 days to several … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

15. #05 DEPRESSION (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/05_depression_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - believe that dysfunction in glutamate neurotransmission may play a major role in the etiology of depressive … symptoms in both bipolar disorder and MDD, although its exact mechanism of action is still unknown … symptoms improved both significantly and rapidly and that these effects lasted from 3 days to several … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

16. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/05_depression_potential_high_impact_june_2012.pdf
    January 01, 2012 - believe that dysfunction in glutamate neurotransmission may play a major role in the etiology of depressive … symptoms in both bipolar disorder and MDD, although its exact mechanism of action is still unknown … symptoms improved both significantly and rapidly, and that these effects lasted from three days to … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

17. #05 DEPRESSION (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/05_depression_potential_high_impact_june_2012.pdf
    January 01, 2012 - believe that dysfunction in glutamate neurotransmission may play a major role in the etiology of depressive … symptoms in both bipolar disorder and MDD, although its exact mechanism of action is still unknown … symptoms improved both significantly and rapidly, and that these effects lasted from three days to … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major

18. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1512.pdf
    December 01, 2015 - and the severity of certain depressive symptoms. … antidepressant, partly due to a hypothesized link between dysfunctional glutamate neurotransmission and depressive … symptoms observed in BPD and MDD.4 Preclinical studies indicate that ketamine’s antidepressant properties … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major … depression.

19. #05 DEPRESSION (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1512.pdf
    December 01, 2015 - and the severity of certain depressive symptoms. … antidepressant, partly due to a hypothesized link between dysfunctional glutamate neurotransmission and depressive … symptoms observed in BPD and MDD.4 Preclinical studies indicate that ketamine’s antidepressant properties … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major … depression.

20. #05 DEPRESSION (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1312.pdf
    October 01, 2014 - Researchers believe that dysfunctional glutamate neurotransmission may play a major role in causing depressive … symptoms in both BPD and MDD, although its exact mechanism of action is still unknown.59,61 Studies … symptoms improved both significantly and rapidly and that these effects lasted from 3 days to several … Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on … Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT- resistant major